- Home
- SKIN vs GNFT Comparison
SKIN vs GNFT Comparison
Compare SKIN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- GNFT
- Stock Information
- Founded
- SKIN 1997
- GNFT 1999
- Country
- SKIN United States
- GNFT France
- Employees
- SKIN N/A
- GNFT 167
- Industry
- SKIN Package Goods/Cosmetics
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKIN Consumer Discretionary
- GNFT Health Care
- Exchange
- SKIN Nasdaq
- GNFT Nasdaq
- Market Cap
- SKIN 199.8M
- GNFT 172.2M
- IPO Year
- SKIN N/A
- GNFT 2019
- Fundamental
- Price
- SKIN $1.52
- GNFT $3.45
- Analyst Decision
- SKIN Hold
- GNFT Strong Buy
- Analyst Count
- SKIN 5
- GNFT 1
- Target Price
- SKIN $2.55
- GNFT $13.00
- AVG Volume (30 Days)
- SKIN 624.5K
- GNFT 6.7K
- Earning Date
- SKIN 02-27-2025
- GNFT 09-19-2024
- Dividend Yield
- SKIN N/A
- GNFT N/A
- EPS Growth
- SKIN N/A
- GNFT N/A
- EPS
- SKIN N/A
- GNFT 0.47
- Revenue
- SKIN $347,620,000.00
- GNFT $86,225,222.00
- Revenue This Year
- SKIN N/A
- GNFT $145.20
- Revenue Next Year
- SKIN $1.79
- GNFT N/A
- P/E Ratio
- SKIN N/A
- GNFT $7.10
- Revenue Growth
- SKIN N/A
- GNFT 175.45
- 52 Week Low
- SKIN $0.91
- GNFT $3.31
- 52 Week High
- SKIN $5.17
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SKIN 45.99
- GNFT 29.68
- Support Level
- SKIN $1.56
- GNFT $3.44
- Resistance Level
- SKIN $1.92
- GNFT $3.90
- Average True Range (ATR)
- SKIN 0.13
- GNFT 0.13
- MACD
- SKIN -0.01
- GNFT 0.01
- Stochastic Oscillator
- SKIN 23.30
- GNFT 2.02
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets, and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.